News Room

Jelfa SA (Poland) Appoints Plexus Ventures as Strategic Advisors

November 1, 2002

Philadelphia, PA - Jelfa SA, a pharmaceutical company based in Jelenia Gora in southwest Poland, has appointed Plexus Ventures to assist its management to develop of a 5-year Strategic Plan. Jelfa, a public company listed on the Warsaw Stock Exchange, is a strong player in the Polish market where it ranks among the top 25 pharmaceutical companies. Jelfa recorded net sales of PLN 243 million (approximately US$ 60 million) in 2001, an 11% increase over the prior year.

The new Strategic Plan will be the first step of a strategic process intended to characterize Jelfa's unique strengths, refocus internal resources, expand the product portfolio and improve operating performance.

Jelfa is a leading Polish producer of ethical pharmaceutical drugs and over-the-counter medications with significant franchises in multivitamins, dermatologicals and injectable drugs. Jelfa’s production facilities meet or exceed GMP standards and the company continues to expand its sales and marketing capabilities. For further information, please consult http://www.jelfa.com.pl.


About Plexus Ventures

Plexus Ventures, founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, Indianapolis, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide. For further information, please consult: http://www.plexusventures.com.